Zucker diabetic fatty rats, a model for type 2 diabetes, develop an inner ear dysfunction that can be attenuated by losartan treatment
- 2 June 2015
- journal article
- Published by Springer Nature in Cell and tissue research
- Vol. 362 (2) , 307-315
Abstract
Hearing loss secondary to diabetes remains under debate. In our study, we used Zucker Diabetic Fatty (ZDF) rats as an animal model of type 2 diabetes to investigate whether (1) hearing ability impairment and structural alterations of the inner ear occur in diabetes and (2) an angiotensin II receptor blocker (losartan) can protect rats from diabetic damage. Homozygous mutants were treated with a placebo or losartan and heterozygous animals served as non-diabetic controls. All animals underwent immunohistochemical and electronmicroscopical analysis. Functional testing of hearing ability was performed by click-evoked auditory brainstem responses. The present study showed significant sensorineural hearing impairment in placebo-treated diabetic rats (hearing threshold, 45.0 ± 2.1 dB SPL) compared to both non-diabetic controls (34.7 ± 4 dB SPL) and losartan-treated diabetic rats (36.1 ± 7.4 dB SPL). Concurrently, the functional decline in the placebo-treated rats was associated with significant morphological abnormalities, particularly in the intermediate cells of the stria vascularis and with strial dysfunction. These degenerative changes were indicated by the down-regulation of several pumps, ionic and cellular channels, which are involved in the cycling of K+ and the maintenance of the endocochlear potential essential for the hearing process. Thus, the inner ear can be regarded as a target organ during hyperglycemic disorders and a metabolically induced “diabetic otopathy” may be added to angiopathy, nephropathy and neuropathy as a specific complication of diabetes mellitus. Blockade of the angiotensin II receptor can prevent this “diabetic otopathy” despite hyperglycemic serum levels.Keywords
This publication has 42 references indexed in Scilit:
- Connexins and DiabetesCardiology Research and Practice, 2012
- Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetesActa Diabetologica, 2011
- Identification and characterization of a functional mitochondrial angiotensin systemProceedings of the National Academy of Sciences, 2011
- Interaction between Mitochondria and the Endoplasmic Reticulum: Implications for the Pathogenesis of Type 2 Diabetes MellitusExperimental Diabetes Research, 2011
- End-Organ Protection in Patients with HypertensionDrugs, 2011
- Contribution of animal models to the research of the causes of diabetesWorld Journal of Diabetes, 2010
- Diabetic Retinal Neurodegeneration Is Associated With Mitochondrial Oxidative Stress and Is Improved by an Angiotensin Receptor Blocker in a Model Combining Hypertension and DiabetesDiabetes, 2009
- Strial microvascular pathology and age-associated endocochlear potential decline in NOD congenic miceHearing Research, 2008
- Molecular and Physiological Bases of the K+ Circulation in the Mammalian Inner EarPhysiology, 2006
- Anatomy and regulation of the central melanocortin systemNature Neuroscience, 2005